Evidence map›Paper›PMID 42060963›Full record

ArticleJACC. Basic to translational science2026

Targeted Intra-Atrial Delivery of GMP-Grade Human Extracellular Vesicles Prevents Inflammation-Driven Postoperative Atrial Fibrillation in Pigs.

Noreen Ahmed, Sandrine Parent, Charlotte A René, Nevena Kovacina, Jennifer St Amant, Melody Napoleone, Berenice Collet, Saad Kahn, David Courtman, Duncan J Stewart and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Moving Beyond the Hype in Extracellular Vesicle Therapy.JACC. Basic to translational science · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Noreen AhmedDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Rhythm Biotherapeutics Inc, Ottawa, Ontario, Canada.
Sandrine ParentDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Charlotte A RenéDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Rhythm Biotherapeutics Inc, Ottawa, Ontario, Canada.
Nevena KovacinaDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Jennifer St AmantDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Melody NapoleoneDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Berenice ColletDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Saad KahnDivision of Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
David CourtmanDivision of Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Duncan J StewartDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Division of Regenerative Medicine, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Vincent ChanDivision of Cardiac Surgery, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Darryl R DavisDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada; Rhythm Biotherapeutics Inc, Ottawa, Ontario, Canada. Electronic address: ddavis@ottawaheart.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted intra-atrial delivery of GMP-grade human cardiac extracellular vesicles (EVs) was evaluated for prevention of postoperative atrial fibrillation (AF). EVs were manufactured under serum-free, xenogen-free GMP-compatible conditions and tested in rat and porcine sterile pericarditis models. In rats, intra-atrial EV delivery resulted in selective atrial retention without systemic toxicity. In pigs, EV administration was technically feasible, well tolerated, and completely prevented spontaneous AF while significantly reducing inducible AF. EV therapy also attenuated atrial inflammation and fibrosis without adverse end-organ effects. These findings support localized cardiac EV therapy as a first-in-human-ready, disease-modifying biologic strategy for postoperative AF prevention.

Indexed as

atrial fibrillationbiologic therapycardiac fibrosisextracellular vesiclesinflammationpostoperative atrial fibrillation

Identifiers

PMID42060963
PMCPMC13141498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.